MoonLake Immunotherapeutics
NASDAQ · MLTX·Zug, Switzerland·Small-cap·Phase 3
Clinical-stage biotech developing sonelokimab, a tri-specific Nanobody that inhibits both IL-17A and IL-17F, for inflammatory skin and joint diseases. Preparing a BLA submission for hidradenitis suppurativa in 2H 2026 based on positive Phase 3 VELA trial results.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| MoonLake Investor Day February 2026 | R&D day | February 1, 2026 | 49 |